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INTRODUCTION
The extraordinarily high world-wide prevalence ofHelicobacterpylori infection has
become apparent over the last decade. Its associated disorders are becoming clearer and
revealing some fascinating paradoxes. For example, duodenal ulcer has been shown to be
"caused" by H. pylori, at least by the near absence of recurrence after eradication of the
infection. Similarly, gastric adenocarcinoma has been strongly associated with H. pylori
infection, but herein lies the paradox, in that, for decades, it has been known that the
development of a duodenal ulcer is protective of the development of gastric cancer. This
has been formally established by Parsonnet and co-workers who demonstrated a negative
correlation between the two disorders [1]. This raises the obvious question as to what
pathogenic mechanisms underlie the evolution of such widely divergent clinical events.
Another seeming paradox concerns the development of duodenal ulcer by H. pylori.
Duodenal ulcer has generally been associated with an increase in gastric acid secretion.
However, upon eradication ofH. pylori, basal acid secretion returns to normal levels, but
peak acid output remains elevated for some time. Does this mean that peak acid secretion
is genotypically determined, or is it a consequence of an increased parietal cell mass
induced by a long-term H. pylori infection? Furtherconfusion has been engendered by an
early observation on the natural history ofpeptic ulcer disease by a general practitioner in
England, who despite the obvious limitations ofhis contemporary diagnostic techniques,
showed that peptic ulcer disease "burns out" over time [2]. Does that mean that gastric
atrophy reduces secretion ofacid to thepointthat Schwartz's dictum of"no acid, no ulcer"
becomes applicable?
This paper will review some of the interactions between H. pylori and the gastric
epithelium that have been studied, to the point that some clues can be obtained as to how
this bacteriumcan evoke such an extraordinary range ofphysiological responses with their
ensuant pathological processes. Clearly, we are only at the very beginning of an under-
standing. Much ofwhat was written on gastric physiology and pathology before Marshall
andWarren's seminal paper [3] needs to be read with caution, in that disease groupings or
physiological responses may need to be reconsidered based on the presence or absence of
H. pylori. Perhaps the oldest example ofthis problem is that ofthe gastric urease that was
thought tobe agastric epithelial enzyme until the discovery ofH.pylori [4]. Even now, the
role ofthe urease is not clear. Its site oflocalization remains controversial; does it remain
intracytoplasmic until it is released on death ofthe organism or is it actively secreted into
the gastric environment [5]? We now have the technology to begin to address these ques-
tions, butironically in the developed world, theprevalence ofnew cases ofH. pyloriinfec-
tion has plummeted [6]. Treatment is becoming very effective thus making it difficult for
investigators to have access to required clinical material.
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We will discuss the pathobiology of H. pylori infection chronologically by arbitrari-
ly dividing the natural history ofinfection into the early, middle and late phases. Certainly
there is overlap between these phases, but this structure does provide a framework for dis-
cussion.
EARLY EVENTS
The natural history ofH. pylori infection is poorly defined. Much ofthe work on this
persistent or "slow infection" [7] is based on extrapolation perforced by the difficulties of
making serial observations on an organism whose natural habitat is difficult to access.
Most observations have been made ofsingle points in time without any real knowledge of
when infection was initiated. Serial observations are comparatively rare. This then makes
interpretation difficult when the investigator is trying to relate that observation to an infec-
tion that may be life-long.
The earliest events of H. pylori infection are quite well described from a series of
observations gleaned from volunteers who ingested the organism and from careful obser-
vation ofresearch volunteers who were inadvertently infected with H. pylori. There are no
data in young children, which is the predominant acquisition time ofinfection, except for
the first report of acute acquired achlorhydria by William Osler [8]. Although in early
childhood there is evidence for infection, loss of infection and further reinfection [9-11],
we know little or nothing about the details of these events. Thus adult infection is the
exception, and we can, for now, only assume that it parallels the events in children.
An oriental volunteer was closely monitored during a study of the effects of aspirin
on the gastric mucosa [12]. He appeared to be infected with H. pylori during an endo-
scopic examination ofhis stomach. In the first few days, he was shown to have an increase
in mucus output, blood loss and DNA release into the gastric lumen. By day eight, he had
become profoundly achlorhydric, and an acute gastritis had developed. He remained
achlorhydric for two months, but overtime, he spontaneously recoveredhis acid secretion.
Marshall voluntarily confirmed Koch's postulates and noted the development of gastritis
within a few days ofingesting 1 x 109 c.f.u ofH. pylori [13]. The gastritis was notable for
the predominance of polymorphonuclear leukocytes. Subsequently, Morris repeated this
experiment in more detail [14]. He initiated infection with 3 x 105 c.f.u. ofH. pylori, hav-
ing failed to induce infection with the same strain that Marshall had ingested. He too
developed a pangastritis with the predominance ofpolymorphonuclear white blood cells,
and eight days after infection developed achlorhydria. Both conditions persisted until day
26 when he took doxycycline. By day 29, his acid production returned to normal, but the
infection and the gastritis persisted.
A larger epidemic of retrospectively diagnosed H. pylori infection thought to have
been transmitted by a contaminated pH probe has provided further useful data. Of37 vol-
unteers who participated in a gastric acid secretion study, 17 developed achlorhydria and
gastritis [15]. Profound achlorhydria was noted three to 75 days after the onset ofclinical
symptoms with a maximal decrease of peak acid output occurring at a mean of 25 days
(range seven to 49 days) after infection. During this period, a severe fundic gastritis was
noted in all those who were achlorhydric, though parietal cells were noted to be morpho-
logically intact. Despite severe neutrophilic gastritis, gastric permeability remained nor-
mal. Pepsinogen 1 levels were substantially elevated butreturned to normal levels. Gastrin
levels were elevated but were similar both during hypochlorhydria and subsequently. Of
particular note is that three ofthe seventeen volunteers did not experience a return ofacid
secretion over 12 months of follow-up. In addition, a patient with Zollinger-Ellison syn-
drome became achlorhydric at the same time and remained so from 1976 to 1978.
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Other observations ofachlorhydria during the early stages ofinfection include a small
epidemic described by Gledhill and co-workers [16]. A number ofisolated occurrences of
achlorhydria have been reported, often in association with contaminated instrumentation.
An additional case of achlorhydria in another case of Zollinger-Ellison syndrome was
reported with prolonged and carefully studied acid secretion [17]. In a study designed to
investigate the prevalence of H. pylori in healthy asymptomatic volunteers, 25 percent of
those who were H. pylori positive were found to be achlorhydric [18].
Animal studies with various Helicobacter species have been reported in which there
was an in vivo correlation with the human studies in that reduced acid secretion appeared
to be an early event. Fox et al. demonstrated the elevation of gastric pH in ferrets within
a few weeks of infection with H. mustelae [19]. A study in beagles showed elevations in
gastric pH in several animals within days after infection with H.felis [20]. No systematic
acid secretory studies have been reported using the non-human primate model, the mouse
model or the gnotobiotic pig. The analogous in vitro experiments have been performed
using H. pylori, H. felis and H. mustelae on rabbit and ferret cells, respectively [21].
Experiments using guinea pig parietal cells and H. pylori yielded similar results [22], as
did the use ofH. pylori and human-derived gastric glands [23].
Thus, early on after infection with H. pylori, at least in adults and probably in chil-
dren, there is a series ofevents that occur thatprofoundly alters gastric physiology. In par-
ticular, there is a severe fundic gastritis associated with an overt neutrophilic infiltrate and
heavy colonization with bacteria. This is followed by the profound loss of acid secretion
that spontaneously recovers in most, but not all individuals. The gastritis appears to start
before achlorhydria develops, and thus, the reduced acid secretion is not part ofthe initial
colonization process. There is the possibility that this period represents a phase during
which excretion of H. pylori can occur as has been demonstrated for H. mustelae. This
organism has been shown to be easily detectable inferret feces duringperiods ofachlorhy-
dria induced by either H. mustelae or by omeprazole [24]. No such data has been report-
ed in man other than two reports ofthe successful isolation ofH. pylori from the feces of
children in the Gambia and from dyspeptic adults in the United Kingdom [11, 25]. Even
the use ofthe highly sensitive polymerase chain reaction (PCR)b has been inconclusive in
demonstrating H. pylori in human feces [26].
MIDDLE PERIOD
Once infection with H. pylori has been initiated and gastritis is established, a number
ofoptions appearpossible. First, in the majority ofindividuals, the gastritis slowly evolves
with areduction but not total loss ofthe neutrophilic infiltrate. The gastritis converts from
the acute pangastritis to a predominantly antral gastritis with lymphocytic, predominantly
Thl cells and monocytic infiltration. In the majority of those infected, this process prob-
ably does not progress further, and a symbiotic relationship develops. There are no known
indicators of how long an individual has been infected with H. pylori. The second possi-
bility is the development ofduodenal ulcerdisease, generally considered to be a condition
of increased acid secretion. The third alternative is for gastric ulceration to develop, gen-
erally noted to be associated with normal to reduced acid secretion. The fourth alternative
is ofthe uncommon event ofpersistent hypochlorhydria. Long-term hypochlorhydria may
be present in the United Kingdom in five percent of those individuals infected with H.
pylori [27]. Finally, infection could terminate either spontaneously by mechanisms
unknown orinadvertently with the use ofantimicrobial agents [28]. Which course an indi-
vidual will follow is at present unpredictable given ourlimited knowledge ofthe virulence
factors related to H. pylori. Our knowledge of the host factors involved is even
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more limited. However, certain observations have been made with regard to physiological
processes that occur in each group.
In the asymptomatic H. pylori infected individual, the gastritis is predominantly
antral in location. This gastritis is associated, in turn, with a reduction in the number ofD
cells that produce somatostatin. G cells appear unaffected, and there is wide agreement
that gastrin levels are generally increased [29]. Basal acid secretion and post-prandial acid
secretion do not appearto be very different between those who are infected and those who
are not. However, gastrin releasing polypeptide (GRP)-stimulated acid secretion is
increased three-fold along with a comparable increase in gastrin release in those infected
with H. pylori [30].
The second scenario applies to those individuals who develop duodenal ulcer disease
in response to H. pylori infection. No data have been reported on the relationship of age
of infection to the development of ulceration. This point of ignorance has two ramifica-
tions: First, we are unlikely to ever rigorously define this relationship, because the inva-
sive nature ofdiagnostic studies precludes frequent observations. Second, this is a signif-
icantpitfall in terms ofcase selection for studies designed to compare differences between
those merely infected with H. pylori and those with ulcers. At present there is no way of
defining whether or not an individual infected with H. pylori may suddenly develop an
ulcer.
The pathophysiology ofH.pylori-induced peptic ulcerdisease is not wellunderstood.
The traditional view that ulcerogenesis occurs when mucosal defensive mechanisms
become overwhelmed by aggressive luminal factors remains a useful paradigm. H. pylori
may promote ulcer development directly, for instance, by elaborating a vacuolating cyto-
toxin, or indirectly by increasing acid secretion (see below). One novel hypothesis is that
H. pylori damages the gastroduodenal mucosaby promoting epithelial cell apoptosis [31].
Recent datahave also been developed indicating that H. pylori may inhibit mucosal bicar-
bonate secretion, an intrinsic defense mechanism of gastric and duodenal mucosa [10].
This area ofresearch is rapidly evolving, and many ofthe current possibilities have been
reviewed [32-34].
Several other recent observation are worth reviewing. Duodenal ulcer is generally
associated with an increase in acid secretion. Until recently, this was assumed to be due
to an increase in parietal cell mass [35] that, in turn, was assumed to be genetically deter-
mined. Three recent observations have been made that on eradication of H. pylori peak
acid output recovers to normal values after a six to 12 month period [36-38]. These obser-
vations can be interpreted as follows: Peak acid secretion, a function ofparietal cell mass,
is not only genetically determined but on long-term infection with H. pylori becomes
increased [37]. The slow reduction ofpeak acid secretion after H. pylori eradication may
reflect the relatively slow turnover ofparietal cells in man.
El-Omar has shown that in duodenal ulcer patients infected with H. pylori the use of
intravenous GRP results in a three-fold increase in gastrin release and a six-fold increase
in acid secretion [30]. This was interpreted as an increased sensitivity of the parietal cell
by mechanisms unknown. The effect of GRP on basal secretion disappeared 12 months
after eradication ofH. pylori, but there remained a significantly elevated response to gas-
trin 17 at 12 months [36]. This finding remains unexplained. In a study by Labenz et al.,
[39] it was shown that both before and after treatment ofH. pylori in those with duodenal
ulcer, 24-hour median gastric pH was about the same, 1.0 and 1.1, respectively. However,
the effect of omeprazole in 17 patients before and after eradication of H. pylori revealed
a surprising difference in gastric pH. Omeprazole was significantly less effective after H.
pylori eradication therapy as assessed by 24-hour intragastric pH measurements. Median
pH went from 5.5 to 3.3 after eradication, superficially a striking change, but it should be
remembered that the reduction from pH 1 to 3.3 is a more than a 99 percent reduction in
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H+ ion concentration. Gillen and McColl (in press, Gut) have performed similar experi-
ments in H. pylori positive patients without ulcers and have demonstrated a more dramat-
ic effect still by measuring gastric acid secretion. In omeprazole-treated individuals, acid
secretion was effectively nil when H. pylori was present, and when the infection was
cured, secretion was significantly increased. Further support for this finding comes from
observations made in patients with Zollinger-Ellison syndrome. Not only do patients with
this syndrome who are H. pylori positive require less proton pump inhibitor therapy, but
their stimulated acid secretion is only about 60 percent that of those infected with H.
pylori, mean maximal acid output being about40 and 66 mEq/hour, respectively [40]. An
explanation forthese findings is notreadily apparent. The data are consistent with the pos-
sibility that H. pylori produces an acid inhibitory factor that works synergistically with
omeprazole. It is not known if this effect is specific for omeprazole or whether it is a
generic property of proton pump inhibitors. An earlier study comparing the effect of
omeprazole and lanzoprazole reported comparable efficacy for both with median 24 hour
pH values of5.5 and 5.4, respectively [41]. PostH. pylori treatment studies were not con-
ducted, but the placebo response was a pH of 1.3. This hypothesis is also consistent with
earlierobservations that omeprazole in volunteers had little antisecretory activity at a dose
of 10 mg, but in ulcer patients there was some clinical activity [18].
The enhanced efficacy ofomeprazole in H. pylori positive patients should be studied
further for two reasons. There has been concern regarding the possibility of accelerated
gastric atrophy in patients with gastroesophageal reflux disease (GERD) who require
long-term omeprazole therapy and also are infected with H. pylori [42]. A recent FDA
panel concluded that the issue was not substantiated. However, the treatment ofH. pylori
may render the control of the GERD more difficult. This is a novel therapeutic dilemma.
Furthermore, there is early evidence that some patients with duodenal ulcer who are treat-
ed successfully for H. pylori subsequently develop symptoms of GERD. This raises the
interesting philosophical issue as to whether this pathogenic organism, found on the gas-
tric mucosa ofgreater that 60 percent ofthe world's population, may also have some ben-
eficial role. This is an ironic twist in that omeprazole has become a major component of
eradication therapy for H. pylori. A further surprise was reported by Banerjee et al. [43]
who found that H. pylori was suppressed by sucralfate, an aluminum sucrose polymer.
This suppression was associated with a reduction ofGRP-stimulated gastrin secretion and
acid secretion. Comparable studies in H. pylori associated gastric ulcers have not been
performed.
Other secretory processes in the gastric epithelium have received much less scrutiny.
Gastric juice vitamin C levels are now well known to be reduced in H. pylori infection,
though serum levels ofthis vitamin remain normal [44]. This may be due, in part, to abac-
terial oxidase, but there may also be an impairment of secretion secondary to the gastritis
[44, 45]. Eradication ofthe organism results in normalization ofluminal vitamin C levels.
Pepsinogen levels are elevated by H. pylori infection, particularly during the acute stage.
Initially, the change in the various pepsinogens was thought to be a genetically determined
event and was used as a marker for duodenal ulcer disease [46]. However, the patterns
returned to normal after eradication of H. pylori [47, 38]. Subsequently there have been
suggestions that pepsin release is mediated by a small molecule produced by H. pylori
[48] or by bacterial lipopolysaccharide [49].
LATE PERIOD
The concept ofa late period ofinfection is obviously arbitrary. However it does serve
to conceptualize several important issues. The vast majority of those infected with H.
47Cave and Goddard: Pathobiology ofH. pylori
pyloricontinue to carry theirinfection with no ill effects. There is some evidenceforspon-
taneous loss ofinfection, but whether this is truly spontaneous or a loss facilitated by the
incidental use of antibiotics is unknown. Acid secretion in the elderly continues in most
individuals unabated. Pepsinogen levels may fall. Duodenal and gastric ulcers are well
known to occur late into life, but are comparatively uncommon.
Atrophy of the gastric mucosa occurs in some individuals over time. What actually
constitutes atrophy is difficult to define. In pernicious anemia, it is comparatively easy
with complete loss ofspecialized elements such as chiefandparietal cells. Is, however, an
intensely inflamed antrum with apparent loss of glandular elements the same as the loss
ofglandular elements in the gastric body with little inflammation? Correa, in 1984, initi-
ated and has popularized the concept of multifocal atrophic gastritis (MAG) [50]. This
entity appears to start in the area ofthe incisura and spread in a patchy manner both prox-
imally into the body and distally into the antral mucosa. However, there are now questions
regarding the relationship of antral gastritis to MAG. This condition is regarded as one of
the phases in the development ofgastric neoplasia along with the development ofintesti-
nal metaplasia [51].
Little is known of the secretory capacity of the stomach during a particular type and
degree ofmucosal atrophy. A recent study suggests that at least some atrophy is function-
ally reversible after eradication of H. pylori [52]. Of particular note is a recent observa-
tion, albeit in mice, that atrophy is a function of the host and not that of the infection.
Large differences in atrophy were observed in mice of different genotypes infected with
the same strain ofH.felis or H. pylori. Furthermore, there was poor correlation between
the degree ofbacterial colonization and the site of atrophy. For example, colonization of
the antrum in C57BL/6 mice at two months was associated with severe body atrophy at
six months [53]. The other issue relating to atrophy is the observation by Fry that the
recurrence of ulcer disease tends to spontaneously enter remission after reaching a peak
period [2]. His observations on the natural history ofulcerdisease, which for obvious rea-
sons cannot be repeated, raise the possibility that atrophy can occur in those who initial-
ly developed ulcer disease. Some support for this comes from the observation that esti-
mates of the parietal cell populations on the margins of partial gastrectomy specimens,
resected for gastric neoplasia orbenign conditions, are almost identical [54]. Sipponen, in
a recent review [55], suggests that in those who hypersecrete acid, gastritis and atrophy
predominate in the antrum and that those who are hyposecreters tend to have atrophy of
the corpus. Clearly, what is needed is much more data on the structure-function relation-
ships between the various anatomical patterns of gastritis and the amount of acid secret-
ed.
CONCLUSION
We conclude with the following hypothesis for the pathobiology of H. pylori infec-
tion. On initial infection, the body of the stomach becomes acutely inflamed and acid
secretion is inhibited. The inflammation is slowly modulated and the organism migrates
to the antrum. Those who develop acid hypersecretion may develop duodenal ulcers; the
majority develop a symbiotic relationship, and a few with predominant corpus infection
have normal to reduced acid secretion and develop gastric ulcers. A small number of
hyposecreters with mucosal atrophy develop carcinoma. The use of proton pump
inhibitors has revealed an unexpected degree of latent acid inhibitory activity associated
with H. pylori that is related, at least in part, to colonization ofthe corpus. In otherwords,
there is a local effect of H. pylori on the parietal cell. Whether this effect is mediated by
ammonia or by some other specific bacterial product is not known.
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